Drugs / ODM-106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02393950 | Mar → Oct 2015 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02393950 ↗ |
| Route | Oral | “Single oral escalating doses of ODM-106 will be administered.” NCT02393950 ↗ |